期刊文献+

DRGs-PPS付费下临床路径在合理控费中的重要作用 被引量:16

The Important Role of Clinical Pathway in Reasonable Cost Control Under DRGs-PPS Payment
原文传递
导出
摘要 目的研究DRGs-PPS付费模式下应用临床路径的重要作用,为医院费用管理提供依据。方法纳入北京市某医疗机构2744例符合临床路径入组标准的病例,将1372例未入组病例和1372例入组并完成临床路径的病例的例均住院费用和费用消耗指数录入SPSS 22.0软件进行配对样本T检验,判断是否入组临床路径在医疗控费中的作用。结果统计分析发现入组并完成临床路径的病例相较于未入组病例的例均费用和费用消耗指数下降具有统计学意义,之后对入组并完成临床路径,但例均费用和费用消耗指数均超过未入组病例进行深入分析,以0C15病组为例,按入组不同的临床路径进行分类统计,发现入组病例的例均费用和费用消耗指数均高于未入组病例,具有统计学意义,研究认为出现此类现象主要是由于临床路径的制定不够合理,该方法可以检验临床路径制定的合理性。结论DRGs-PPS付费模式下临床路径无论是在医疗费用控制、医疗质量管理及病案首页质控中均发挥着重要作用。 Objective Tostudy the important role of applying clinical pathway under DRGs-PPS payment mode.Methods To study 2744 cases,1372 cases of them were not included in the clinical pathway and 1372 cases of them were included in and completed the clinical path in a medical institution in Beijing.Their average medical cost and cost consumption index were recorded into SPSS 22.0 software for paired sample T-test to determine whether the clinical path played a role in medical cost control.Results It found in groups and finish the cases compared with clinical pathway into the group,all the cases costs and expenses consumption index decreased statistically significant,after the into the group and complete the clinical pathway,but cases of both cost and cost consumption i ndex,analyzi ng than not i nto the group of cases with OC15 disease group as an example,accordi ng to the different set of clinical pathvway to statistical classification,independent sample T-test analysis found that the group of cases all costs and expenses consumption index were higher than in the cases into the group,and statistically significant,This method could be used to test the rationality of clinical pathway formulation.Conclusions Under DRGs-PPS payment mode,clinical pathway would play an important role in medical cost control,medical quality management and medical record quality control.
作者 李超 窦婧婧 宋景晨 潘琦 盖媛媛 陈彤 Li Chao;Dou Jingjing;Song Jingchen;Pan Qi;Gai Yuanyuan;Chen Tong(Department of Medical Services,Beijing Hospital,Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;不详)
机构地区 北京医院医务处
出处 《中国病案》 2020年第9期43-46,共4页 Chinese Medical Record
基金 北京医院院级科研课题(bj-2018-049)
关键词 临床路径 DRGS 医疗费用控制 Clinical pathway DRGs Medical cost control
作者简介 通信作者:陈彤
  • 相关文献

参考文献8

二级参考文献64

  • 1周宇,郑树忠,孙国桢.德国DRG付费制度的借鉴[J].中国卫生资源,2004,7(4):186-187. 被引量:31
  • 2黄慧英.诊断相关分类法在北京地区医院管理中的可行性研究[J].中华医院管理杂志,1994,10(3):131-136. 被引量:101
  • 3徐小炮,尹爱田,王利燕.美国DRGs支付制度对我国医疗支付方式改革的启示[J].中国卫生经济,2007,26(3):76-78. 被引量:45
  • 4北京市DRG-PPS项目组.北京版诊断相关分组(BJ-DRG)研究和开发项目报告[R].北京:北京市卫生局,2010.
  • 5Patel M. Implications of Diagnosis Related Groups(DRGs)for the management of hospitals[J]. Medecine Sociale Et Preventive, 1986, 31(3): 174-177.
  • 6Kris V, Massimiliano P, Ruben van Z, et al. An overview on the history and concept of care pathways as complex interventions [J]. International Journal of Care Pathways, 2010, 14(3): 117-123.
  • 7Jason C. Development and implementation of a clinical pathway program in an acute care general hospital in Singapore [J]. International Journal for Quality in Health, 2000, 12(5): 403-412.
  • 8Leigh K, Thomas R, Erica J, et al. What is a clinical pathway? Development of a definition to infolan the debate[J]. BMC Medicine, 2010(8): 31.
  • 9De Bleser L, Depreitere R, De Waele K, et al. Defining Pathways[J]. Journal of Nursing Management, 2006, 14(7): 553-563.
  • 10Richard F A, John M, Jmnes G, et al. All Patient Refined Diagnosis Related Groups(APR-DRGs)version 20.0[R]. Wallingford: Clinical Research and Documentation Departments of 3M Health Information Systems, 2003.

共引文献151

同被引文献162

引证文献16

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部